"These drugs have been proven to be harmful for us. Most of the countries worldwide have already banned them. Moreover, this toxicity - proven in many of these drugs - decreases the body resistance to fight any disease," said a senior AIIMS doctor.
For example, Nimesulide - a drug which can cause liver damage, especially among children suffering from viral infection - is banned in the US, UK and Australia. As a result, the Indian government has now banned its nine different combinations.
According to the Ranjit Roy committee set up by health ministry, the country has an unacceptably large number of drug formulations in the market - somewhere between 60,000 and 85,000. "Many of these medicines should not have been allowed to reach the market in the first place," it said.
The committee, which submitted its report in July 2013, expressed its surprise as to "how such a situation has come to pass". "Such a massive drug consumption leads to body getting immune to the medicine's effect itself. The situation becomes dangerous as a stronger drug is needed to kill the same bacteria," said the doctor.
The government, understanding the seriousness of situation, set up a new panel, under the chairmanship of Professor Chandrakant Kokate, to review the safety and efficacy of one category of drugs - fixed dose combinations (FDCs). Consequently, it banned 344 FDCs last Thursday.
"I have to give my patients directly the second or third line of treatment when they come to me. Earlier, they used to get well in 2-3 days. Now, they take 7-8 days. Their body has become immune to antibiotics due to its continuous usage," said a Gurgaon-based pulmonologist.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)